Clinical trial · Observational
Drug Response Testing and Repurposing Using Glioblastoma Organoid
Patient-derived Organoids As Predictive Models for Drug Response Testing and Repurporsing in Glioblastoma Therapy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this observational study, based on a prospectively collected cohort, is to evaluate the prognostic value of patient-derived organoids in predicting responses to conventional and repurposing drugs, including temozolomide, in patients with primary or recurrent glioblastoma. The primary question is whether the patient's response to temozolomide is recapitulated in their corresponding patient-derived glioblastoma organoid (GBO). Patient drug responses are evaluated using survival data, while GBO drug responses are assessed through a drug-response testing platform utilizing cell viability assays. Additionally, this platform is used to explore the potential application of various chemotherapeutic agents.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Glioblastoma | Glioblastoma | CURATED_BROADER | 0.80 |
| Organoid | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Organoid-based drug sensitivity test | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- glioblastoma
- description
- prospectively enrolled
- interventionNames
- Other: Organoid-based drug sensitivity test
Primary outcomes (1)
- measure
- progression-free survival
- timeFrame
- 12 months after surgery
- description
- Radiologic progression time following the RANO 2.0 criteria
Secondary outcomes (1)
- measure
- overall survival
- timeFrame
- 18 months after surgery
- description
- patient survival time
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * primary or recurrent glioblastoma * patients treated with standard treatment including surgery and temozolomide based chemoradiation therapy * sufficient tumor sample is available for organoid culture Exclusion Criteria: * patients who are not underwent concurrent chemoradiation therapy (CCRT) following surgery * failed to obtain MRI scan after CCRT * patients refusal
References
Publications (0)
Data not yet available